(Reuters) – Chinese pharma major CSPC Pharmaceutical Group said on Thursday it has signed a strategic partnership with Pfizer to launch a local brand of a COVID-19 oral therapeutic treatment in China.
(Reporting by Archishma Iyer in Bengaluru; Editing by Sherry Jacob-Phillips)
